Alirocumabum在一家多学科医院中的实践：一项开放，非比较性前瞻性研究的结果

目的

在实际临床实践中评估在患有动脉粥样硬化血脂异常的患者中使用Alirocumabum的疗效和安全性。

材料和方法

一项前瞻性，非对照研究研究了92例（61名男性；平均年龄59.8±9.6岁）患有动脉粥样硬化血脂异常且未能达到目标脂质水平的患者。Alirocumabum的剂量为150 mg，每2周一次，皮下注射，持续3个月。主要终点是达到低密度脂蛋白胆固醇的目标水平。此外，还评估了脂蛋白（a）和高密度脂蛋白胆固醇的水平。为了评估安全性，检查了肝试验，肌酐水平和血糖，已经研究了副作用。为了检验统计假设，使用了配对t检验和威尔克森符号秩检验。

结果

3个月后，治疗中观察到低密度脂蛋白胆固醇的降低有统计学意义：1.45 [0.99；2.14] vs 最初的3.00 mmol / l [2.17;3.81]（p <0.0001）；中位数下降幅度为–47％[–25;–65]; 40名（43％）患者达到低密度脂蛋白胆固醇的目标水平。3个月后，发现高密度脂蛋白胆固醇增加。治疗时，其水平为1.36±0.41 vs最初的1.31±0.38 mmol / L（p <0.01）。在基线> 30 mg / dL的21例患者中重新测量了脂蛋白（a）的浓度：3个月后，统计学上显着降低。67 [46;  155] vs 85mg/dl[58; 187]（p <0.001）。肝功能检查，肌酐和空腹血糖指标没有明显变化。 没有记录到副作用和不良反应。

结论

在实际的临床实践中，三个月后。 用Alirocumabum治疗后，观察到低密度脂蛋白胆固醇水平显着下降，43％的患者达到了目标水平，脂蛋白（a）水平显着下降，高密度脂蛋白胆固醇升高。

1. Stols-Gonçalves D., Hovingh G.K., Nieuwdorp M., Holleboom A.G. NAFLD and atherosclerosis: two sides of the same dysmetabolic coin? Trends Endocrinol Metab. 2019 Dec; 30(12): 891–902. https://doi.org/10.1016/j.tem.2019.08.008 PMID: 31630897

2. Assis D.N. Chronic complications of cholestasis: evaluation and management. Clin Liver Dis. 2018; 22(3): 533–44. https://doi.org/10.1016/j.cld.2018.03.014 PMID: 30259851

3. Hüsing A., Kabar I., Schmidt H.H. Lipids in liver transplant recipients. World J Gastroenterol. 2016; 22(12): 3315–24. https://doi.org/10.3748/wjg.v22.i12.3315 PMID: 27022213

4. Madhwal S., Atreja A., Albeldawi M., et al. Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies. Liver Transpl. 2012; 18: 1140–6. https://doi. org/10.1002/lt.23508 PMID: 22821899. Erratum in: Liver Transpl. 2013 Jan; 19(1): 113. Albeldawdi, Mazen [corrected to Albeldawi, Mazen]. https://doi.org/10.1002/lt.23594 PMID: 22821899

5. Balmer M.L., Dufour J.F. Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. Swiss Med Wkly. 2008 Jul 26; 138(29–30): 415–9. PMID: 18654866

6. Burman B.E., Jhaveri M.A., Kowdley K.V. An update on the treatment and follow-up of patients with primary biliary cholangitis. Clin Liver Dis. 2017; 21(4): 709–23. https://doi.org/10.1016/j.cld.2017.06.005 PMID: 28987258

7. Roth E.M., Davidson M.H. PCSK9 inhibitors: mechanism of action, efficacy, and safety. Rev Cardiovasc Med. 2018; 19(S1): S31–46. PMID: 30207556

8. Tomlinson B., Hu M., Zhang Y., et al. Alirocumab for the treatment of hypercholesterolemia. Expert Opin Biol Ther. 2017; 17(5): 633–43. https://doi.org/10.1080/14712598.2017.1305354 PMID: 28277798

9. Steg P.G., Szarek M., Bhatt D.L., et al. Effect of alirocumab on mortality after acute coronary syndromes. Circulation. 2019; 140(2): 103–12. https://doi.org/10.1161/CIRCULATIONAHA.118.038840 PMID: 31117810

10. Leiter L.A., Tinahones F.J., Karalis D.G., et al. Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabet Med. 2018; 35(12): 1742–51. https://doi.org/10.1111/dme.13817 PMID: 30183102

11. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. European Heart Journal. 2020; 41: 111–88. https://doi.org/10.1093/eurheartj/ehz455 PMID: 31591002

12. Stroes E., Guyton J.R., Lepor N., et al. Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study. J Am Heart Assoc. 2016 Sep 13; 5(9). PII: e003421. https://doi.org/10.1161/JAHA.116.003421 PMID: 27625344

13. Theocharidou E., Papademetriou M., Reklou A., et al. The role of PCSK9 in the pathogenesis of non-alcoholic fatty liver disease and the effect of PCSK9 inhibitors. Curr Pharm Des. 2018; 24(31): 3654–7. https://doi.org/10.2174/1381612824666181010123127 PMID: 30317984